Fat Science

Could you have metabolic dysfunction even at a normal weight?
This episode challenges everything we've been taught about weight and health. Dr. Cooper reveals that up to 25% of normal-weight people have metabolic syndrome, yet they're rarely screened because doctors assume they're healthy based on appearance alone.
KEY TAKEAWAYS
Weight and metabolic health are not the same thing - you can be metabolically unhealthy at any size

Normal weight people with metabolic dysfunction are often overlooked and undertreated by healthcare providers

Key screening tests include fasting glucose, insulin, HbA1c, triglycerides, HDL cholesterol, blood pressure, and inflammatory markers like HSCRP

Metabolic dysfunction can start in your 20s and take decades to develop into serious disease

Both normal weight and higher weight patients face bias - normal weight people aren't screened enough, while higher weight people have everything blamed on their weight

Early screening and treatment can prevent catastrophic health outcomes later in life

The liver plays a crucial role in metabolism and can become insulin resistant regardless of body weight

NOTABLE QUOTE
"You cannot tell anything about someone's health from their outside, what they look like or what, even what they're doing necessarily, but definitely not their body size. So you can be healthy or unhealthy at any size body, and I think that's what's overlooked quite a bit." — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Appendix: Key References
Primary literature supporting this episode
•       Wang et al. Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. Journal of Clinical Endocrinology & Metabolism, 2023.
•       Review: Beyond BMI — Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Journal of Clinical Medicine, December 2025.
•       Korean meta-analyses on metabolic dysfunction phenotypes and cardiometabolic risk, Cardiovascular and Metabolic Sciences Journal review, 2024.
•       Frontiers in Nutrition, January 2026. Associations of metabolic heterogeneity with the progression of cardiometabolic multimorbidity.
•       International Journal of Obesity, September 2025. Cardiovascular risk factors associated with metabolic health phenotypes.
Mechanism references
•       MASLD — metabolic dysfunction-associated steatotic liver disease — nomenclature and clinical framework. AASLD/EASL consensus, 2023.
•       Insulin signaling, adipose tissue dysfunction, and ectopic fat deposition — reviews on the upstream-downstream relationship.
•       Epicardial adipose tissue and cardiovascular dysfunction — Frontiers in Cardiovascular Medicine, January 2026.
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told your metabolism is broken and there's nothing you can do about it?
This mailbag episode tackles tough questions about medication effectiveness, unexpected side effects, and the complex realities of treating metabolic dysfunction. Dr. Cooper addresses why some people regain weight while still on GLP-1s, explores the connection between hair loss and weight loss medications, and explains why leptin levels can remain stubbornly low even with proper nutrition.
KEY TAKEAWAYS
Weight regain while on GLP-1 medications is more common than most people realize

Hair loss from weight loss medications is usually related to nutrient deficiencies, not the medication itself

Leptin dysfunction involves both hormone levels and signaling pathways throughout the body

Hypoglycemia after meals often indicates complex metabolic issues that require specialized testing

Starting elderly patients on GLP-1s requires careful monitoring of nutrition, blood pressure, and side effects

Mechanical eating differs from intuitive eating and remains important even when medications are working

Annual weight loss rates of 10% or higher indicate medications are still effective

NOTABLE QUOTE
"It is not uncommon to see the weight go up while on these meds, contrary to what people think. They're great, but we always wanna point out some people don't even respond to these." — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Ever wonder why you can improve your health but still feel like you're failing because the scale isn't cooperating?
Dr. Cooper breaks down groundbreaking new clinical guidelines from three major obesity organizations that are completely reframing what success in obesity treatment actually means. For the first time, these groups are saying quality of life, energy levels, and overall health matter more than the number on the scale.
KEY TAKEAWAYS
Three major obesity organizations worked collaboratively to issue guidelines prioritizing quality of life over weight loss as primary treatment goals

Guidelines explicitly address medical stigma as a structural barrier to care requiring systemic change

Treatment is positioned as long-term management similar to other chronic conditions like thyroid disorders

Document notably avoids calorie restriction language, focusing instead on healthy lifestyle alongside medication

Setmelanotide receives strong recommendation for rare genetic obesity conditions with available genetic testing

Strong medication recommendations now include GLP-1s like semaglutide and tirzepatide, plus bupropion-naltrexone combination

NOTABLE QUOTE
"Nobody ever asked. Nobody ever looked. Nobody ever said anything. I was like, 'I think there's something wrong with my metabolism or something because I'm not eating a ton.' They're like, 'Well, you must be.' And I'm like, 'N- n- no, I don't think so. I mean, unless it's happening when I'm sleeping. I don't know.'" — Andrea Taylor
Reference Link
Alexander L, Purnell JQ, et al. Pharmacological management of obesity in adults: a clinical guidance statement from The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition. Obesity. 2026;34(4):851–870. doi:10.1002/oby.70164 https://onlinelibrary.wiley.com/doi/10.1002/oby.70164 
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told you have PCOS but nothing seems to help?
In May 2024, after 14 years of global collaboration involving 56 organizations and 22,000 stakeholders, the medical community officially changed PCOS to PMOS - and the reason why reveals everything that's been wrong with how this condition has been understood and treated for decades. Dr. Cooper breaks down why this isn't just a name change, but a complete reframe that puts metabolic dysfunction at the center where it belongs.
KEY TAKEAWAYS
PCOS is now officially called PMOS - Polyendocrine Metabolic Ovarian Syndrome - shifting focus from ovarian problems to metabolic dysfunction
70 million women globally are affected during reproductive years, with 70% remaining undiagnosed
The condition can occur at any weight and is driven by insulin resistance and other metabolic signals, not ovarian problems
Treatment should focus on metabolic health rather than weight loss or ovarian interventions
The name change parallels similar shifts in medicine like MASLD replacing non-alcoholic fatty liver disease
NOTABLE QUOTE
"Most patients with this label that they've had in the past, the PCOS label, feel a sense of hopelessness, and even join support groups and things like that, and thinking that this will be a condition they have forever. And what I try to do is explain, no, this is just a physical manifestation of the metabolic disruption that we treat all the time" — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
 
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Have you been told it's just calories in calories out while your lived experience says otherwise?
In this mailbag episode, Dr. Cooper addresses complex metabolic questions from listeners worldwide. From eating disorders requiring specialized care to GLP-1 plateau management, each question reveals how individual biology trumps one-size-fits-all solutions.
KEY TAKEAWAYS
Eating disorders like anorexia require comprehensive medical team treatment, not self-management approaches

Side effects from GLP-1 medications often improve with consistent eating patterns and adequate nutrition

The calories in calories out model ignores the biological complexity of how your body actually burns fuel

PCOS responds well to metabolic treatments because it's driven by underlying insulin and hunger hormone imbalances

Sleep deprivation and chronic stress significantly impact GLP-1 effectiveness and overall metabolic function

Bioidentical progesterone may help perimenopause sleep issues without the metabolic side effects of older formulations

Stroke survivors may experience hypothalamic obesity that responds remarkably well to GLP-1 medications

NOTABLE QUOTE
"If that really worked, imagine, you know, would we actually need these sophisticated medications that are so groundbreaking? Would we have had decades and decades, or actually centuries of failed, you know, diet experiences by so many people?" — Dr. Emily Cooper
Links & Resources
Podcast Home: fatsciencepodcast.com
Cooper Center for Metabolism: coopermetabolic.com
Resources from Dr. Cooper: coopermetabolic.com/resources
Join Our Community: patreon.com/cw/FatSciencePodcast
Submit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com
Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.
This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.